Hepatic Disease

Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.

The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.

Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.

Resmetirom vs placebo led to significantly greater proportion of adults reaching NASH resolution without increased fibrosis and with fibrosis improvement by ≥1 stage.

The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.

Your daily dose of the clinical news you may have missed.

Findings suggest that SGLT2 inhibitors may be the preferred choice for patients with both T2D and NAFLD, reported researchers.

Using FIB-4 index first to screen for cirrhosis may lead to clinicians missing 48% of cases, according to a recent study.

Risk of mortality from ALD and MetALD was significantly higher among women even though both phenotypes were more prevalent among men, a new study reveals.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Screening for fibrosis in persons at risk of ALD and MASLD led to sustained improvements in lifestyle, eg, reduced alcohol consumption, weight loss, and increased exercise.

Less than a quarter of persons with cirrhosis who are diagnosed with osteoporosis are started on treatment, reported researchers.

The new guideline underscores the need to overcome barriers to alcohol use disorder treatment and expand multidisciplinary care for patients with ALD.

Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.

Reducing stigma associated with chronic liver disease and expediting diagnosis and referral will take some time but progress is being made, Luxon says.

Transplant hepatologist Dr Bruce Luxon says primary care is essential to making progress against chronic liver disease but doesn't have the resources it needs.

Simplified risk stratification tools for NAFLD, effects of statins on hepatic disease, trends in OHE, and patient perspectives are samples of the noteworthy research areas.

Arun Jesudian, MD, details key findings from a study he recently presented at The Liver Meeting 2023.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.

TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.

More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.

One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.

TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.

TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.